ZymoGenetics lines up $100M

ZymoGenetics has lined up $100 million in fresh financing from Deerfield Management. ZymoGenetics can tap that money in $25 million allotments anytime over the next 18 months. And each tranche will reward Deerfield in a two percent royalty stream from the biotech's Recothrom, a blood-clotting drug. Deerfield will also receive 1.5 million warrants priced at $10.34 on the first draw and a million warrants on each subsequent draw priced at 25 percent above the 15-day average share price. Release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.